Research programme: T cell receptor based therapies - GigaMune
Latest Information Update: 28 Aug 2023
At a glance
- Originator GigaMune
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders; Cancer
Most Recent Events
- 20 Jul 2023 Early research in Autoimmune disorders in USA (Parenteral) (GigaMune pipeline, July 2023)
- 20 Jul 2023 Early research in Cancer in USA (Parenteral) (GigaMune pipeline, July 2023)